AzTrials
AzTrials

Adnexal Tumor of SkinCARADERMNCT03210935

French National Database of Rare Dermatological Cancers

An observational study of Adnexal Tumor of Skin and Merkel Cell Carcinoma, run by University Hospital, Lille at 34 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. Read more about this study

Who is it for?
Any age
How many people
9,000 participants
Where
34 sitesFrance
Study dates
24 Nov 2015to 31 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Who may be able to join

  • Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Who cannot join

  • Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
  • Patients refusal

Trial locations and contacts

34 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Laurent MORTIER, MD,PhD contact

03.20.44.41.93 ext. +33

laurent.mortier@chru-lille.fr

Benoit Minart contact

benoit.minart@chru-lille.fr

34 sites in 1 country

France34 sites, 34 recruiting

  • CHU Amiens Picardie

    Amiens

    Catherine Lok, MD

    Recruiting

  • CHU Angers

    Angers

    Ludovic Martin, MD

    Recruiting

  • CH Annecy Gennevois

    Annecy

    Julie De Quatrebarbes, MD

    Recruiting

  • CHU Besançon

    Besançon

    François Aubin, MD

    Recruiting

  • CHU Avicenne

    Bobigny

    Eve Maubec, MD

    Recruiting

  • CHU Ambroise Paré

    Boulogne-Billancourt

    Philippe Saiag, MD

    Recruiting

  • CHU de Brest

    Brest

    Laurent Misery, MD

    Recruiting

  • CHU de Caen

    Caen

    Laurence VERNEUIL, MD, PhD

    Laurence VERNEUIL, MD, PhD

    Recruiting

  • CHU de Clermont Ferrand

    Clermont-Ferrand

    Michel d'Incan, MD

    Recruiting

  • CHU Bocage

    Dijon, Dijon, 21079

    sophie DALAC, md, 03 80 29 33 36, sophie.dalac@chu-dijon.fr

    Recruiting

  • CHU de Grenoble

    Grenoble

    Marie-Therese Leccia, MD

    Recruiting

  • CH Le Mans

    Le Mans, Le Mans, 72037

    Nathalie BENETON-BENHARD, md, 02 43 43 43 58, nbeneton@ch-lemans.fr

    Recruiting

  • CHU de Limoges

    Limoges

    Christophe Bedane, MD

    Recruiting

  • Centre Léon Bérard

    Lyon

    Patrick Combemasle, MD

    Recruiting

  • Hôpital La Timone

    Marseille

    Jean Jacques Grob, MD

    Recruiting

  • Hôpital St Eloi

    Montpellier

    Bernard Guillot, MD

    Recruiting

  • CHU de Nancy

    Nancy

    Florence Granel-Brocard, MD

    Recruiting

  • CHU Nantes - Place Alexis Ricordeau

    Nantes

    Brigitte DRENO, MD, PhD

    Brigitte DRENO, MD, PhD

    Recruiting

  • CHU de Nice

    Nice

    Jean Philippe Lacour, MD

    Recruiting

  • CHR d'Orleans

    Orléans

    Guido Bens, MD

    Recruiting

  • CHU Bichat

    Paris

    Vincent Descamps, MD

    Recruiting

  • CHU Cochin

    Paris

    Selim Aractingi, MD

    Recruiting

  • CHU St Louis

    Paris

    Celeste Lebbe, MD

    Recruiting

  • CHU de Bordeaux

    Pessac

    Marie BEYLOT-BARRY, MD, PhD

    Marie BEYLOT-BARRY, MD, PhD

    Recruiting

  • Centre hospitalier Lyon Sud

    Pierre-Bénite, Pierre-benite, 69495

    luc THOMAS, md,phd, 04 78 86 16 79, luc.thomas@chu-lyon.fr

    Recruiting

  • CHU de Pointe à Pitre

    Pointe à Pitre

    Nadège Cordel, MD

    Recruiting

  • CHU de Poitiers

    Poitiers

    Gerard Guillet, MD

    Recruiting

  • CHU de Reims

    Reims

    Florent Grange, MD

    Recruiting

  • CHU de Rennes

    Rennes

    Alain Dupuy

    Recruiting

  • CHU de Rouen

    Rouen

    Pascal JOLY, MD, PhD

    Pascal JOLY, MD, PhD

    Recruiting

  • CHU de Strasbourg

    Strasbourg

    Dan Lipsker, MD

    Recruiting

  • CHU de Toulouse - Larrey

    Toulouse

    Nicolas MEYER, MD, PhD

    Nicolas MEYER, MD, PhD

    Recruiting

  • CHU de Tours

    Tours

    Laurent Machet, MD

    Recruiting

  • Institut Gustave Roussy

    Villejuif

    Caroline ROBERT, MD, PhD

    Caroline ROBERT, MD, PhD

    Recruiting

Other trials in France

About this study

Official title: French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes.

CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :

  • to provide epidemiological, clinical and socio-economic characteristics of patients
  • to identify new clinical or epidemiological prognostic factors for these rare cancers
  • to evaluate the impact of various treatments on outcomes
Read the detailed description

CARADERM is a French national multidisciplinary project which will prospectively enroll from 37 French centers any patient presenting with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment or cutaneous adnexal carcinoma.

A structured and centralized database of clinical monitoring of patients will be established. Information captured will include clinical constitutional factors, factors linked to primary carcinoma, factors linked to lymph node involvement, "American Joint Committee on Cancer" (AJCC) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical, radiotherapy and palliative strategies) with evaluation of response, date of death, date of latest news.

Keywords
Adnexal cutaneous carcinoma, Merkel cell carcinoma, Advanced basal cell carcinoma requiring systemic treatment
Medical subject headings
Carcinoma, Merkel Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03210935
Study groupRoleWhat they receive
Merkel cell carcinomaNot described
Advanced basal cell carcinomaNot described
Cutaneous adnexal carcinomasNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence and natural history of the 3 types of rare skin cancers

    Measured: 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2017
  2. Study start24 Nov 2015
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
9,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03210935
Sponsor's protocol ID
NI_2014_60
Acronym
CARADERM
Status last verified
May 2026
First submitted
4 Jul 2017
Last updated
22 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Adnexal Tumor of Skin and Merkel Cell Carcinoma, run by University Hospital, Lille at 34 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 34 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Laurent MORTIER, MD,PhD (03.20.44.41.93 ext. +33, laurent.mortier@chru-lille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence and natural history of the 3 types of rare skin cancers (time frame: 10 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03210935.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in